Edition:
United States

BioLine RX Ltd (BLRX.TA)

BLRX.TA on Tel Aviv Stock Exchange

409.80ILa
27 Mar 2017
Change (% chg)

-0.10 (-0.02%)
Prev Close
409.90
Open
409.80
Day's High
409.80
Day's Low
409.80
Volume
1
Avg. Vol
129,286
52-wk High
533.00
52-wk Low
287.50

Latest Key Developments (Source: Significant Developments)

BiolineRX announces acquisition of Agalimmune Ltd
Thursday, 23 Mar 2017 07:00am EDT 

BiolineRX Ltd : Biolinerx announces acquisition of Agalimmune Ltd to accelerate expansion of immuno-oncology pipeline . BiolineRX Ltd - acquisition consideration consisted of a $6 million upfront payment .BiolineRX ltd - acquisition consideration consisted of $3 million in cash and remainder in biolineRX shares.  Full Article

Biolinerx reports Q3 financial results
Tuesday, 22 Nov 2016 08:00am EST 

Bioline Rx Ltd : Bioline RX Ltd - operating loss for three months ended September 30, 2016 amounted to $4.5 million versus operating loss of $3.6 million .Biolinerx reports third quarter 2016 financial results.  Full Article

BioLine, I-Bridge Capital establish new drug development JV in China
Thursday, 25 Aug 2016 07:00am EDT 

Bioline RX: Bioline RX and I-Bridge Capital establish a new drug development joint venture in china .Under terms of JV agreement, each partner will provide seed capital of one million dollars to venture.  Full Article

Bioline RX Ltd Q2 loss per share $0.07
Thursday, 11 Aug 2016 07:15am EDT 

Bioline Rx Ltd : Biolinerx reports second quarter 2016 financial results .Qtrly loss per share $0.07.  Full Article

Biolinerx signs second clinical immuno-oncology collaboration agreement
Monday, 8 Aug 2016 07:00am EDT 

Bioline RX LTD :Biolinerx signs second clinical immuno-oncology collaboration agreement to investigate combination of bl-8040 and Keytruda® for pancreatic cancer.  Full Article

BioLineRx reports net loss for Q1 of $3.5 mln
Tuesday, 17 May 2016 08:09am EDT 

BioLineRx Ltd: BioLineRx reports first quarter 2016 financial results .Net loss for three months ended March 31, 2016 amounted to $3.5 million , compared with a net loss of $4.3 million.  Full Article

BioLine Rx Ltd Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions
Monday, 23 Nov 2015 07:00am EST 

BioLine Rx Ltd:BioLine RX Ltd .Biolinerx announces initiation of phase 1/2 trial for novel treatment in two bone marrow failure conditions.Interim results of study, in patients with hypoplastic myelodysplastic syndrome and aplastic anemia, expected by end of 2016.  Full Article

BioLine Rx Ltd reports positive clinical results from first part of ph-2 trial in r/r AML
Thursday, 5 Nov 2015 09:00am EST 

BioLine Rx Ltd:Biolinerx announces positive clinical results from first part of phase 2 trial in r/r aml.Results showed that bl-8040, as a single agent and in combination with cytarabine (ara-c), was safe and well tolerated at all doses.Bl-8040 was safe and well tolerated at all doses tested up to and including highest dose level of 1.5 mg/kg, with no major adverse events.Says are continuing to perform and plan multiple additional clinical studies for bl-8040.  Full Article

BioLine Rx Ltd announces regulatory submission for phase 2 trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia
Thursday, 10 Sep 2015 07:00am EDT 

BioLine Rx Ltd:Says it has filed regulatory submissions required to commence Phase 2 trial for BL-8040, in combination with standard-of-care immunosuppressive therapy, as a novel treatment for two bone marrow failure conditions: hypoplastic myelodysplastic syndrome and aplastic anemia.Says the trial is expected to commence shortly after receipt of regulatory approval, anticipated in the next few months.  Full Article

BioLine Rx Ltd announces top-line results from bellerophon's preservation i clinical trial for bioabsorbable cardiac matrix
Monday, 27 Jul 2015 06:00am EDT 

BioLine Rx Ltd:Biolinerx announces top-line results from bellerophon's preservation i clinical trial for bioabsorbable cardiac matrix (bl-1040).Study showed no statistically significant difference between patients treated with bcm versus placebo for both primary and secondary endpoints.On track to report top-line data from our phase 2 clinical study of bl-8040 for treating relapsed/refractory aml in Q4 2015.Expect to meet with FDA in order to discuss next steps in clinical development program for indication.  Full Article

More From Around the Web

BRIEF-BiolineRX announces acquisition of Agalimmune Ltd

* Biolinerx announces acquisition of Agalimmune Ltd to accelerate expansion of immuno-oncology pipeline